DISCLAIMER: This guide is educational content for research and informational purposes only. Cagrilintide is an investigational compound not yet approved by the FDA or EMA. It is not approved for human use outside clinical trials. This content does not constitute medical advice, and users should consult with a qualified healthcare provider before using any investigational peptides. Self-administration of unapproved compounds carries significant legal, regulatory, and health risks.
Cagrilintide is a long-acting acylated amylin analogue developed for once-weekly subcutaneous injection. It functions as a full agonist at amylin receptors (AMY1, AMY2, AMY3), which suppress appetite, reduce glucagon secretion, and delay gastric emptying. The fatty acid acylation allows albumin binding, extending its half-life to approximately 7 days and enabling weekly dosing rather than daily injections.
The compound is being investigated primarily as a combination therapy with semaglutide (marketed as CagriSema in development), which demonstrates superior fat loss outcomes compared to either drug alone. As monotherapy, cagrilintide shows consistent but modest weight loss effects. Clinical evidence supports its efficacy for metabolic control and body weight reduction, particularly in individuals with obesity and type 2 diabetes.
Current evidence tier for fat loss: Tier 4 (strong human RCT evidence, especially in combination)
Current evidence tier for muscle preservation: Tier 1 (no human data; in-vitro studies show transient ATP reduction)
Typical cost: $200–$600 per month
Route: Subcutaneous injection only
Cagrilintide follows a dose-escalation protocol to minimize gastrointestinal side effects, particularly nausea, which is the most commonly reported adverse effect during early treatment phases.
Standard escalation ladder:
- Week 1–2: 0.16 mg once weekly
- Week 3–4: 0.32 mg once weekly
- Week 5–6: 0.64 mg once weekly
- Week 7–8: 1.2 mg once weekly
- Week 9+: 2.4 mg once weekly (maintenance/target dose)
Each dose increase should occur only if the previous dose was well-tolerated. If nausea or vomiting is severe, remain at the current dose for an additional 1–2 weeks before escalating.
Standard 12–16 week introduction and assessment cycle:
- Weeks 1–8: Dose escalation phase (0.16 mg → 2.4 mg)
- Weeks 9–16: Maintenance phase at 2.4 mg once weekly
- Weeks 17+: Extended maintenance or cycle off
Most users remain on cagrilintide continuously once at maintenance dose, as it is designed for chronic use rather than pulsed cycling. However, if side effects become intolerable or a user wishes to assess outcomes off-compound, a full washout takes 3–4 weeks (approximately 5 half-lives at ~7 days per half-life).
- Once weekly, same day each week (e.g., every Monday)
- Administer at the same time of day for consistency
- Rotate injection sites to minimize lipohypertrophy (thigh, abdomen, upper arm)
Objective: Maximize body weight and fat mass reduction
Typical cycle: 16–24 weeks at maintenance dose (2.4 mg once weekly)
Adjunct nutrition: Moderate caloric deficit (300–500 kcal/day below maintenance)
Protocol:
- Follow standard escalation through week 8
- Maintain 2.4 mg once weekly for a minimum of 8 weeks
- Expected weight loss: 13.7% in individuals with type 2 diabetes; up to 22–23% when combined with semaglutide
- As monotherapy, expect 3–5% additional weight loss above placebo baseline
- Monitor body composition at weeks 8, 12, and 16 to confirm fat loss vs. lean mass loss
Indicators to continue:
- Sustained appetite suppression after week 4
- Progressive weight loss at weeks 8, 12, and 16 (minimum 0.5–1% per week)
- Stable blood glucose or improved postprandial glucose control
- Tolerable GI side effects (nausea resolves by week 4–6 in most users)
Objective: Improve glycemic control and reduce HbA1c
Typical cycle: Indefinite maintenance; designed for chronic use
Protocol:
- Follow standard escalation
- Maintain 2.4 mg once weekly indefinitely
- Cagrilintide reduces glucagon secretion and slows gastric emptying, improving postprandial glucose control
- Work with an endocrinologist to adjust other diabetes medications (insulin, metformin, sulfonylureas) as glycemic control improves
- Monitor HbA1c at baseline, week 12, and week 24; adjust other medications accordingly to prevent hypoglycemia
Expected outcomes:
- HbA1c reduction of 1.0–1.5% in many users, particularly when combined with semaglutide
- Improved fasting glucose and postprandial glucose peaks
- Reduced insulin requirements if on exogenous insulin
Objective: Maximize weight loss and cardiometabolic benefits
Typical protocol: Parallel escalation of both compounds
Co-administration strategy:
- Both compounds are administered once weekly via subcutaneous injection
- Inject on the same day but at different injection sites
- Escalate both compounds simultaneously:
- Weeks 1–2: Cagrilintide 0.16 mg + Semaglutide 0.25 mg
- Weeks 3–4: Cagrilintide 0.32 mg + Semaglutide 0.5 mg
- Weeks 5–6: Cagrilintide 0.64 mg + Semaglutide 1.0 mg
- Weeks 7–8: Cagrilintide 1.2 mg + Semaglutide 1.7 mg
- Weeks 9+: Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Expected outcomes:
- 22–23% mean body weight reduction vs. 2–5% placebo
- 10.9 mmHg systolic blood pressure reduction vs. 2.8 mmHg placebo
- 63% of participants reach BP targets vs. 32% placebo
- Superior fat loss compared to either drug alone
Caution: Combination therapy increases gastrointestinal side effects (RR: 1.32 vs. semaglutide alone). Nausea and vomiting may be more pronounced. Slower escalation or extended maintenance at lower doses may be necessary.
Cagrilintide is typically supplied as a lyophilized powder in single-dose vials.
Supplies needed:
- Sterile 0.9% sodium chloride (normal saline) for injection
- 29–31 gauge insulin syringe (0.3–0.5 mL capacity)
- Alcohol prep pad
- Sterile gauze
Steps:
- Inspect the vial for cracks or discoloration. Do not use if compromised.
- Wipe the rubber stopper with an alcohol prep pad and allow to dry (30 seconds).
- Draw up the appropriate volume of sterile saline (exact volume depends on desired concentration; follow provided instructions, typically 1–2 mL).
- Insert the needle into the vial at an angle, pushing saline into the vial slowly.
- Gently swirl (do not shake vigorously) to dissolve the powder. Wait 1–2 minutes for complete dissolution.
- Invert the vial and draw up the prescribed dose using a fresh syringe and needle.
- If not injecting immediately, store the reconstituted solution at 2–8°C (36–46°F) for up to 24 hours.
- Confirm dose and injection site
- Inspect the solution for particles or discoloration; discard if present
- Wash hands with soap and water
- Wipe injection site with alcohol prep pad and allow to air-dry
- Do not touch the injection site after sterilization
- Pinch a fold of skin at the injection site (abdomen, thigh, or upper arm).
- Insert the needle at a 45–90 degree angle, piercing the skin and subcutaneous tissue.
- Inject the full dose slowly and steadily (over 3–5 seconds).
- Withdraw the needle and release the skin fold.
- Apply light pressure with gauze if bleeding occurs.
- Do not rub the injection site.
Rotate sites systematically to minimize lipohypertrophy:
- Week 1: Right abdomen, 2 inches left of umbilicus
- Week 2: Left abdomen, 2 inches right of umbilicus
- Week 3: Right thigh, mid-quadriceps
- Week 4: Left thigh, mid-quadriceps
- Week 5: Right upper arm, outer shoulder
- Week 6: Left upper arm, outer shoulder
- Repeat cycle
Unopened vials:
- Store at 2–8°C (36–46°F) in original packaging
- Do not freeze
- Shelf life: typically 24–36 months from manufacture (verify with supplier)
- Transport in a cooler with ice packs if traveling
Reconstituted solutions:
- Refrigerate at 2–8°C (36–46°F) immediately after reconstitution
- Use within 24 hours
- Do not freeze reconstituted solutions
Room temperature storage (if refrigeration unavailable):
- Unopened vials can be stored at up to 25°C (77°F) for up to 28 days in original packaging
- Document the date first removed from refrigeration
| Week | Dose | Side Effects Anticipated | Monitoring Focus |
|---|
| 1–2 | 0.16 mg weekly | Mild nausea, decreased appetite | Tolerability; food intake patterns |
| 3–4 | 0.32 mg weekly | Nausea may peak; early satiety | GI tolerance; meal size reduction |
| 5–6 | 0.64 mg weekly | Nausea may persist; vomiting possible | Body weight (weekly); appetite log |
| 7–8 | 1.2 mg weekly | Nausea typically resolving; diarrhea/constipation | Weight loss trajectory; energy levels |
| 9–12 | 2.4 mg weekly | Minimal side effects; stable appetite suppression | Body composition; blood glucose if diabetic |
| 13–16 | 2.4 mg weekly (maintenance) | Nausea rare; appetite suppressed | Weight loss plateau assessment; body recomposition |
Week 8 assessment point: Evaluate total weight loss, GI tolerance, and energy. If side effects are intolerable, consider extending maintenance at 1.2 mg weekly rather than escalating to 2.4 mg.
Week 16 decision point: If results are satisfactory, continue indefinitely at 2.4 mg weekly. If minimal weight loss and well-tolerated, verify compliance and assess caloric intake (cagrilintide requires a caloric deficit to be effective).
- Mild appetite suppression may begin within hours
- Some users report mild nausea or stomach discomfort
- Injection site: mild redness or swelling (resolves within 24 hours)
- Appetite suppression noticeable but mild
- Food intake reduced by 10–15%
- Mild nausea in 20–40% of users; typically brief
- Energy levels stable or slightly elevated
- Minimal weight loss (0–0.5 lbs)
- Appetite suppression increases noticeably
- Food intake reduced by 25–40%
- Nausea peaks in many users during weeks 3–4, typically resolving by week 6
- Vomiting possible but uncommon if escalation is slow
- Early satiety pronounced; small meals feel sufficient
- Steady weight loss begins: 0.5–1.5 lbs per week
- Blood glucose may improve if diabetic (within days)
Weeks 5–8 (1.2 mg Escalation to Maintenance)
- Appetite suppression stabilizes at high levels
- Nausea resolves in most users by end of week 6
- Sustained food intake reduction (30–40%)
- Consistent weekly weight loss: 1–2 lbs per week in caloric deficit
- Gastrointestinal side effects (diarrhea, constipation) may emerge in weeks 5–7; typically transient
- Energy levels return to baseline or improve as nausea resolves
- Blood pressure may begin to decline (data primarily from combination with semaglutide)
Weeks 9–12 (2.4 mg Maintenance)
- Maximal appetite suppression achieved
- Nausea absent or minimal in most users
- Stable food intake 30–50% below pre-treatment baseline
- Consistent weight loss if caloric deficit maintained: 1–2 lbs per week
- Cumulative weight loss at week 12: typically 5–10 lbs depending on starting weight and caloric deficit
- Blood glucose improvements plateau (if diabetic)
- Injection site reactions become rare
Weeks 13–16+ (Extended Maintenance)
- All side effects minimal or absent
- Appetite suppression remains strong and stable
- Weight loss plateauing as body weight decreases and deficit becomes proportionally smaller
- Opportunity to assess true efficacy: if weight loss stalls despite appetite suppression, caloric intake may be creeping upward; dietary compliance should be reassessed
- Blood pressure further reduced (combination therapy data)
- Long-term tolerability excellent in most users
Error: Advancing to the next dose before completing a full 2-week cycle at the current dose.
Consequence: Severe nausea, vomiting, and poor tolerability; increased risk of treatment discontinuation.
Fix: Strictly adhere to the 2-week escalation intervals unless explicitly directed otherwise by a healthcare provider. If side effects are intolerable, delay advancement by 1–2 weeks.
Error: Assuming cagrilintide alone produces weight loss without intentional caloric restriction.
Consequence: Minimal or no weight loss despite appetite suppression, because the suppressed appetite just brings intake closer to maintenance (not below it).
Fix: Maintain a 300–500 kcal daily deficit below calculated maintenance energy expenditure. Track food intake via a food scale and app (e.g., MyFitnessPal) for at least the first 8 weeks. Appetite suppression is a tool, not an automatic result.
Error: Injecting into the same location repeatedly (e.g., same abdomen quadrant every week).
Consequence: Lipohypertrophy (fatty lumps), reduced drug absorption, injection site pain, and possible abscess formation.
Fix: Use the 6-site rotation schedule provided above. Visually inspect and palpate previous injection sites before each injection.
Error: Leaving reconstituted solution at room temperature for >2 hours or freezing a reconstituted vial.
Consequence: Loss of potency or degradation of the peptide; reduced efficacy or no effect.
Fix: Reconstitute immediately before injection, or refrigerate at 2–8°C for no more than 24 hours. Never freeze reconstituted solutions. Keep unopened vials in the refrigerator at 2–8°C.
Error: Continuing to escalate doses while experiencing worsening nausea, expecting it to resolve.